Targeting chemokines in proteinuria-induced renal disease

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 8, 2012, Pages 833-845

  Moreno, Juan Antonio ^a   Moreno, Sara ^b   Rubio Navarro, Alfonso ^a   Sastre, Cristina ^a   Blanco Colio, Luis Miguel ^a   Gómez Guerrero, Carmen ^a   Ortiz, Alberto ^a,c   Egido, Jesús ^a,c  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b INIA   (Spain)

^c Section of Nephrology   (Spain)

Author keywords

Chemokines; Inflammation; Proteinuria; Renal diseases

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; AUTOANTIBODY; AZD 5672; CARBOXYETHYLGERMANIUM SESQUIOXIDE; CCL1 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; EOTAXIN; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MARAVIROC; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; MONOCYTE CHEMOTACTIC PROTEIN 5; NEUTRALIZING ANTIBODY; RANTES; REPARIXIN; REPAXIRIN; RS 504393; SPIEGELMER; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ALPORT SYNDROME; APOPTOSIS; BIOLOGICAL ACTIVITY; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULUS FILTRATION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATION; INTRACELLULAR SIGNALING; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; KIDNEY TUBULE ABSORPTION; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PROTEINURIA; REPERFUSION INJURY; REVIEW;

ANIMALS; CHEMOKINES; HUMANS; KIDNEY DISEASES; PROTEINURIA; RECEPTORS, CHEMOKINE;

EID: 84863951597     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.703657     Document Type: Review

References (103)

1. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000;68(1):1-8
2. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999;286(5447): 2098-2102
3. Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998;393(6685):595-9
4. Broxmeyer HE, Kim CH. Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities. Exp Hematol 1999;27(7):1113-23
5. Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001;345(11):833-5
6. Reiser J, von Gersdorff G, Loos M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004;113(10):1390-7
7. D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int 2003;63(3):809-25
8. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003;63(4):1468-74
9. Bertani T, Cutillo F, Zoja C, et al. Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 1986;30(4):488-96
10. Ohse T, Inagi R, Tanaka T, et al. Albumin induces endoplasmic reticulum stress and apoptosis in renal proximal tubular cells. Kidney Int 2006;70(8):1447-55
11. Alvarez V, Quiroz Y, Nava M, et al. Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 2002;283(5):F1132-41
12. Anders HJ, Frink M, Linde Y, et al. CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 2003;170(11):5658-66
13. Eardley KS, Zehnder D, Quinkler M, et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int 2006;69(7):1189-97
14. Zoja C, Donadelli R, Colleoni S, et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int 1998;53(6):1608-15
15. Lai KN, Leung JC, Chan LY, et al. Interaction between proximal tubular epithelial cells and infiltrating monocytes/T cells in the proteinuric state. Kidney Int 2007;71(6):526-38
16. Viedt C, Dechend R, Fei J, et al. MCP-1 induces inflammatory activation of human tubular epithelial cells: Involvement of the transcription factors, nuclear factor-kappaB and activating protein-1. J Am Soc Nephrol 2002;13(6):1534-47
17. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 2012;30(1):49-59
18. Holmes WE, Lee J, Kuang WJ, et al. Structure and functional expression of a human interleukin-8 receptor. Science 1991;253(5025):1278-80
19. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270(45):27348-57
20. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52(1):145-76
21. Tang S, Leung JC, Abe K, et al. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest 2003;111(4):515-27
22. Segerer S, Cui Y, Eitner F, et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 2001;37(3):518-31
23. Donadelli R, Zanchi C, Morigi M, et al. Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways. J Am Soc Nephrol 2003;14(10):2436-46
24. Umehara H, Bloom ET, Okazaki T, et al. Fractalkine in vascular biology: From basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004;24(1):34-40
25. Segerer S, Hughes E, Hudkins KL, et al. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int 2002;62(2):488-95
26. Suzuki Y, Lopez-Franco O, Gomez-Garre D, et al. Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: Role of endothelin-1. Am J Pathol 2001;159(5):1895-904
27. Wang Y, Chen J, Chen L, et al. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 1997;8(10):1537-45
28. Takaya K, Koya D, Isono M, et al. Involvement of ERK pathway in albumin-induced MCP-1 expression in mouse proximal tubular cells. Am J Physiol Renal Physiol 2003;284(5):F1037-45
29. Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995;47(6):1546-57
30. Donadelli R, Abbate M, Zanchi C, et al. Protein traffic activates NF-kB gene signaling and promotes MCP-1-dependent interstitial inflammation. Am J Kidney Dis 2000;36(6):1226-41
31. Mezzano S, Aros C, Droguett A, et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004;19(10):2505-12
32. Takase O, Hirahashi J, Takayanagi A, et al. Gene transfer of truncated IkappaBalpha prevents tubulointerstitial injury. Kidney Int 2003;63(2):501-13
33. Rangan GK, Wang Y, Tay YC, Harris DC. Inhibition of nuclear factor-kappaB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 1999;56(1):118-34
34. Sanz AB, Sanchez-Nino MD, Ramos AM, et al. NF-kappaB in renal inflammation. J Am Soc Nephrol 2010;21(8):1254-62
35. Izquierdo MC, Sanz AB, Mezzano S, et al. TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney Int 2012;81(11):1098-107
36. Segerer S, Banas B, Wornle M, et al. CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis. Am J Pathol 2004;164(2):635-49
37. Yoshimoto K, Wada T, Furuichi K, et al. CD68 and MCP-1/CCR2 expression of initial biopsies reflect the outcomes of membranous nephropathy. Nephron Clin Pract 2004;98(1):c25-34
38. Wu H, Wang Y, Tay YC, et al. DNA vaccination with naked DNA encoding MCP-1 and RANTES protects against renal injury in adriamycin nephropathy. Kidney Int 2005;67(6):2178-86
39. Huber TB, Reinhardt HC, Exner M, et al. Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 2002;168(12):6244-52
40. Lee EY, Chung CH, Khoury CC, et al. The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am J Physiol Renal Physiol 2009;297(1):F85-94
41. Kang YS, Lee MH, Song HK, et al. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int 2010;78(9):883-94
42. Ding M, Cui S, Li C, et al. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med 2006;12(9):1081-7
43. D'Haese JG, Demir IE, Friess H, Ceyhan GO. Fractalkine/CX3CR1: Why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther Targets 2010;14(2):207-19
44. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: Basic chemokinese grammar for immune cells. Annu Rev Immunol 2004;22:891-928
45. Segerer S, Bohmig GA, Exner M, et al. When renal allografts turn DARC. Transplantation 2003;75(7):1030-4
46. Vielhauer V, Allam R, Lindenmeyer MT, et al. Efficient renal recruitment of macrophages and T cells in mice lacking the Duffy antigen/receptor for chemokines. Am J Pathol 2009;175(1):119-31
47. Wenzel U, Schneider A, Valente AJ, et al. Monocyte chemoattractant protein-1 mediates monocyte/macrophage influx in anti-thymocyte antibodyinduced glomerulonephritis. Kidney Int 1997;51(3):770-6
48. Fujinaka H, Yamamoto T, Takeya M, et al. Suppression of anti-glomerular basement membrane nephritis by administration of anti-monocyte chemoattractant protein-1 antibody in WKY rats. J Am Soc Nephrol 1997;8(7):1174-8
49. Furuichi K, Wada T, Iwata Y, et al. CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J Am Soc Nephrol 2003;14(10):2503-15
50. Shimizu H, Maruyama S, Yuzawa Y, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 2003;14(6):1496-505
51. Laborde E, Macsata RW, Meng F, et al. Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. J Med Chem 2011;54(6):1667-81
52. Zhang YJ, Rutledge BJ, Rollins BJ. Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. J Biol Chem 1994;269(22):15918-24
53. Ble A, Mosca M, Di Loreto G, et al. Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. Am J Nephrol 2011;34(4):367-72
54. Kulkarni O, Eulberg D, Selve N, et al. Anti-Ccl2 spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas (lpr) mice. J Pharmacol Exp Ther 2009;328(2):371-7
55. Mizoue LS, Sullivan SK, King DS, et al. Molecular determinants of receptor binding and signaling by the CX3C chemokine fractalkine. J Biol Chem 2001;276(36):33906-14
56. Inoue A, Hasegawa H, Kohno M, et al. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 2005; 52(5):1522-33
57. Dorgham K, Ghadiri A, Hermand P, et al. An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. J Leukoc Biol 2009;86(4):903-11
58. Duthey B, Hubner A, Diehl S, et al. Anti-inflammatory effects of the GABA (B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol 2010;19(7):661-6
59. Wan Y, Evans RM. Rosiglitazone activation of PPARgamma suppresses fractalkine signaling. J Mol Endocrinol 2010;44(2):135-42
60. Yadav AK, Lal A, Jha V. Association of circulating fractalkine (CX3CL1) and CX3CR1(+)CD4(+) T cells with common carotid artery intima-media thickness in patients with chronic kidney disease. J Atheroscler Thromb 2011;18(11):958-65
61. Wu X, Wittwer AJ, Carr LS, et al. Cytokine-induced neutrophil chemoattractant mediates neutrophil influx in immune complex glomerulonephritis in rat. J Clin Invest 1994;94(1):337-44
62. Garcia GE, Xia Y, Harrison J, et al. Mononuclear cell-infiltrate inhibition by blocking macrophage-derived chemokine results in attenuation of developing crescentic glomerulonephritis. Am J Pathol 2003;162(4):1061-73
63. Garcia GE, Truong LD, Li P, et al. Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis. Am J Pathol 2007;170(5):1485-96
64. Bizzarri C, Beccari AR, Bertini R, et al. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 2006;112(1):139-49
65. Salmon M, Carpenter DC, Dehaas CJ, et al. Inhibition of LPS-induced neutrophil recruitment in the lungs correlates with modulation of neutrophil CD11b expression using the selective CXCR2 receptor antagonist SB-656933. Eur Respir J 2004;24(Suppl 48):218s
66. Bedke J, Nelson PJ, Kiss E, et al. A novel CXCL8 protein-based antagonist in acute experimental renal allograft damage. Mol Immunol 2010;47(5):1047-57
67. Miura M, Fu X, Zhang QW, et al. Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury. Am J Pathol 2001;159(6):2137-45
68. Sayyed SG, Hagele H, Kulkarni OP, et al. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 2009;52(11):2445-54
69. Anders HJ, Ninichuk V, Schlondorff D. Progression of kidney disease: Blocking leukocyte recruitment with chemokine receptor CCR1 antagonists. Kidney Int 2006;69(1):29-32
70. Chow F, Ozols E, Nikolic-Paterson DJ, et al. Macrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injury. Kidney Int 2004;65(1):116-28
71. Vielhauer V, Berning E, Eis V, et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 2004;66(6): 2264-2278
72. Ninichuk V, Gross O, Reichel C, et al. Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am Soc Nephrol 2005;16(4):977-85
73. Pease JE, Horuk R. Chemokine receptor antagonists: Part 2. Expert Opin Ther Patents 2009;19(2):199-221
74. Basak A, Charvat TT, Chen W, et al. Heteroaryl sulfonamides and CCR2. 2008
75. Sullivan TJ, Dairaghi DJ, Krasinski A, et al. Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications. J Pharmacol Exp Ther 2012 Jun 5. [Epub ahead of print] PMID:22378937
76. Pasternak A, Goble SD, Struthers M, et al. Discovery of a potent and orally bioavailable CCR2 and CCR5 dual antagonist. ACS Med Chem Lett 2010;1(1):14-18
77. Tang WW, Qi M, Warren JS. Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int 1996;50(2):665-71
78. Kang Y, Wu Z, Lau TC, et al. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant. J Biol Chem 2012;287(20):16499-509
79. Pham K, Luo D, Liu C, Harrison JK. CCL5, CCR1 and CCR5 in murine glioblastoma: Immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5. J Neuroimmunol 2012;246(1-2):10-17
80. Cumming JG, Tucker H, Oldfield J, et al. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis. Bioorg Med Chem Lett 2012;22(4):1655-9
81. Gerlag DM, Hollis S, Layton M, et al. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum 2010;62(11):3154-60
82. Fleishaker DL, Garcia Meijide JA, Petrov A, et al. Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebocontrolled trial. Arthritis Res Ther 2012;14(1):R11
83. Patel K, Dixit VD, Lee JH, et al. The GHS-R blocker D-[Lys3] GHRP-6 serves as CCR5 chemokine receptor antagonist. Int J Med Sci 2012;9(1):51-8
84. Darisipudi MN, Kulkarni OP, Sayyed SG, et al. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am J Pathol 2011;179(1):116-24
85. Zheng C, Cao G, Xia M, et al. Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist. Bioorg Med Chem Lett 2011;21(5):1442-6
86. Norman P. A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916.Expert Opin Ther Patents 2011;21(12):1919-24
87. Kothandan G, Gadhe CG, Cho SJ. Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: A combined in silico study. PLoS One 2012;7(3):e32864
88. Maeda DY, Quinn MT, Schepetkin IA, et al. Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism. J Pharmacol Exp Ther 2009;332(1):145-52
89. De Kruijf P, van Heteren J, Lim HD, et al. Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor. J Pharmacol Exp Ther 2009;329(2):783-90
90. Bertini R, Allegretti M, Bizzarri C, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury. Proc Natl Acad Sci USA 2004;101(32):11791-6
91. Cugini D, Azzollini N, Gagliardini E, et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 2005;67(5):1753-61
92. Holz O, Khalilieh S, Ludwig-Sengpiel A, et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010;35(3):564-70
93. Bird JE, Giancarli MR, Kurihara T, et al. Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice. Kidney Int 2000;57(1):129-36
94. Banas B, Wornle M, Berger T, et al. Roles of SLC/CCL21 and CCR7 in human kidney for mesangial proliferation, migration, apoptosis, and tissue homeostasis. J Immunol 2002;168(9):4301-7
95. Wasilewska A, Zoch-Zwierz W, Taranta-Janusz K, Kolodziejczyk Z. Urinary monocyte chemoattractant protein-1 excretion in children with glomerular proteinuria. Scand J Urol Nephrol 2011;45(1):52-9
96. Lepenies J, Eardley KS, Kienitz T, et al. Renal TLR4 mRNA expression correlates with inflammatory marker MCP-1 and profibrotic molecule TGF-beta(1) in patients with chronic kidney disease. Nephron Clin Pract 2011;119(2):c97-c104
97. Wang J, Zou H, Li Q, et al. The expression of monocyte chemoattractant protein-1 and C-C chemokine receptor 2 in post-kidney transplant patients and the influence of simvastatin treatment. Clin Chim Acta 2006;373(1-2):44-8
98. Eardley KS, Kubal C, Zehnder D, et al. The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 2008;74(4):495-504
99. El-Shehaby A, Darweesh H, El-Khatib M, et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 2011;31(5):848-56
100. Tam FW, Sanders JS, George A, et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant 2004;19(11):2761-8
101. Huang F, Horikoshi S, Kurusu A, et al. Urinary levels of interleukin-8 (IL-8) and disease activity in patients with IgA nephropathy. J Clin Lab Anal 2001;15(1):30-4
102. Rovin BH, Song H, Birmingham DJ, et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005;16(2):467-73
103. Tian S, Li J, Wang L, et al. Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare. Inflamm Res 2007;56(7):304-10